[Determination of the quantum requirements for photosynthesis by very thin cell suspensions].

O. Warburg

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

Joshua Paterson,Zhi-hua Li,X. Wen,E. Masih-Khan,Hong Chang,J. Pollett,S. Trudel,A. Stewart

DOI: https://doi.org/10.1111/j.1365-2141.2004.04814.x

2004-03-01

British Journal of Haematology

Abstract:Dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the translocation t(4;14)(p16;q32) occurs in 15% of multiple myeloma (MM) patients and confers a growth and survival advantage to malignant plasma cells. As FGFR3 is a molecular target, we assessed the therapeutic potential of the FGFR‐specific tyrosine kinase inhibitors SU5402 and SU10991 in MM. SU5402 inhibited FGFR3 phosphorylation in vitro and in murine MM tumour models. B cells dependent on FGFR3 for survival were specifically sensitive to SU5402. A panel of 11 human myeloma cell lines was studied, five bearing the t(4;14) translocation. The KMS11 human myeloma cell line, which expresses constitutively active mutant FGFR3, displayed an 85% decrease in S‐phase cells, a 95% increase in G0/G1 cells, and 4·5‐fold increase in apoptotic cells after 72 h treatment with 10 μmol/l SU5402. Activated extracellular signal‐regulated kinases 1 and 2 and signal transducer and activator of transcription 3 were rapidly down‐regulated after SU5402 treatment. In human myeloma cell lines expressing wild‐type FGFR3 the stimulating effect of aFGF ligand was abrogated by SU5402 treatment. Myeloma cells lacking the t(4;14) or with the t(4;14) and a secondary RAS mutation did not respond to therapy. These findings support the development of clinical trials of early intervention with FGFR3 inhibitors in t(4;14) myeloma.
Continuous brainstem auditory evoked potential monitoring during nocturnal sleep.

G. Litscher

DOI: https://doi.org/10.3109/00207459508994297

International Journal of Neuroscience

Abstract:Continuous monitoring of brainstem auditory evoked potentials (BAEPs) was performed simultaneously with polysomnographic recordings during nocturnal sleep in 9 normal males (mean age 25.3 +/- 2.7 years). Four-channel electroencephalography, respiration (abdominal and thoracic), rectal temperature, electrocardiography, electrooculography, chin electromyography, non-invasive blood pressure (Finapres), oxygen saturation and two channels of BAEPs were recorded by a multivariable computer system. All data except BAEPs were preprocessed, integrated over 30 s and printed on a single sheet. Sleep stages were classified visually. Latencies, interpeak latencies, amplitudes and the I/V amplitude ratio of the BAEPs were analysed in the awake state and different sleep stages. The results confirm that, as previously reported, the slight BAEP latency modifications observed during sleep are correlated to body temperature variations. The analysis of the absolute amplitudes of BAEPs showed insignificant (ANOVA) variations with sleep (e.g., mean amplitude of peak V +/- SD: wakefulness = .36 microV +/- .11, REM = .22 microV +/- .05, stage 2 = .27 microV +/- .14, stage 3 = .25 microV +/- .14, stage 4 = .26 microV +/- .11). A significant change between wakefulness and deep sleep could be found in the latencies of wave IV and V and in the amplitude ratio I/V (P < .05, ANOVA, Student-Newman-Keuls method).
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy

Ajay Kumar

DOI: https://doi.org/10.1517/14712598.2014.904851

2014-04-05

Expert Opinion on Biological Therapy

Abstract:INTRODUCTION: Existing pharmacological therapies with basal insulins are limited by weight gain and hypoglycemia, while those with glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are limited by issues of efficacy when used alone. However, when used in combination they show a complementarity of action, in terms of reducing the incidence of hypoglycemia while providing sufficient glycemic control, that might help counterbalance their individual limitations. Clinical trials have demonstrated better efficacy and safety profile of this combination. Insulin degludec/liraglutide (IDegLira) is a once-daily fixed-dose combination of ultra-long-acting basal insulin degludec (IDeg) and GLP-1 RA, liraglutide.AREAS COVERED: We reviewed published data regarding chemistry, pharmacokinetics, pharmacodynamics, clinical efficacy and safety of IDeg, liraglutide and the co-formulation. Literature was searched from the electronic medical database PubMed up to December 2013.EXPERT OPINION: Preliminary studies on IDegLira indicate improved overall glycemic control, better safety profile with reduction in bodyweight and low rate of hypoglycemia compared to IDeg but higher rates of hypoglycemia than liraglutide therapy alone. Further, simplicity of fixed-dose combination offers an additional advantage of improved treatment adherence. IDegLira might be used similar to basal insulins in the current treatment algorithms, but with a greater preference for initiation instead of two or more oral drugs.

medicine, research & experimental,biotechnology & applied microbiology
A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges

Allen B. King,Athena Philis-Tsimikas,Eric S. Kilpatrick,Irene H. Langbakke,Kamilla Begtrup,Tina Vilsbøll

DOI: https://doi.org/10.1089/dia.2016.0405

2017-04-01

Abstract:BACKGROUND: Reducing glycemic fluctuation is important for optimal diabetes management. This post hoc analysis examined glycemic fluctuations and the proportion of subjects achieving recommended blood glucose targets with the fixed ratio combination of insulin degludec and liraglutide (IDegLira) compared to insulin degludec (IDeg) and liraglutide alone.METHODS: We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.RESULTS: Compared with IDeg, IDegLira resulted in a greater proportion of subjects with SMBG values within target ranges (3.9-9.0 mmol/L) than IDeg for all pre- and postprandial values, and for the full nine-point profile (P < 0.05 for all). IDegLira also resulted in a greater reduction in the range of SMBG values over 24 h than IDeg (P ≤ 0.0001). CGM data showed that IDegLira provided greater reductions in interstitial glucose (IG) fluctuation (P = 0.0018) and postprandial IG increment (P = 0.0288) compared with IDeg. Compared with liraglutide, IDegLira brought a higher proportion of subjects within SMBG target ranges (all pre- and all postprandial values, and the full nine-point profile, P < 0.01 for all) and resulted in a greater reduction of time outside the IG target range (P = 0.0072). IDegLira also reduced mean IG more than liraglutide (P < 0.0001).CONCLUSIONS: Treatment with IDegLira allows more patients with T2D to maintain blood glucose within target ranges throughout the day than either IDeg or liraglutide alone.

endocrinology & metabolism
Collaborative Filtering for Predicting Users' Potential Preferences

Kenta Oku,Ta Son Tung,Fumio Hattori

DOI: https://doi.org/10.1007/978-3-642-23866-6_5

2011-09-12

Abstract:
Prognosis of cerebral embolism.

A. Carter

DOI: https://doi.org/10.1016/S0140-6736(65)91473-X

IF: 202.731

1965-09-11

The Lancet

Abstract:
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

Liana K. Billings,Bue F. Ross Agner,Yuksel Altuntas,Randi Grøn,Natalie Halladin,David C. Klonoff,Nikolaos Tentolouris,Esteban Jódar

DOI: https://doi.org/10.1177/1932296820906888

2020-02-28

Journal of Diabetes Science and Technology

Abstract:Background: Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin (HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics. Materials and Methods: DUAL VII trial participants (type 2 diabetes [T2D], HbA1c 53-86 mmol/mol [7.0%-10.0%]) were subgrouped post hoc based on the following baseline characteristics: HbA1c (≤58.5, >58.5 to ≤69.4, and >69.4 mmol/mol; ≤7.5%, >7.5 to ≤8.5%, and >8.5%), body mass index (<30, ≥30 to <35, and ≥35 kg/m 2 ), age (18 to <65 and ≥65 years), duration of diabetes (≥0 to 10 and ≥10 years), total pretrial daily basal insulin dose (20 to <30, ≥30 to <40, and ≥40 to ≤50 U), and fasting plasma glucose (<7.2 mmol/L/<130 mg/dL and ≥7.2 mmol/L/≥130 mg/dL). Results: Compared with BB, and in all subgroups, IDegLira treatment consistently gave similar HbA1c reductions, less severe or blood glucose-confirmed hypoglycemia, lower end-of-trial (EOT) total daily insulin dose, and weight loss. In all subgroups, mean EOT HbA1c was ≤53 mmol/mol (≤7.0%). The greatest HbA1c reduction occurred in the highest baseline HbA1c subgroup. Overall, mean EOT daily insulin dose was 0.43 to 0.52 U/kg with IDegLira and 0.74 to 1.07 U/kg with BB. More participants achieved the triple composite endpoint (HbA1c <53 mmol/mol [ 58.5 to ≤69.4 mmol/mol [41.1% vs 8.3%], and >69.4 mmol/mol [23.8% vs 3.4%]). Conclusion: These results support initiating IDegLira in patients with varying baseline characteristics and uncontrolled T2D on basal insulin. ClinicalTrials.gov registration: NCT02420262
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

Ildiko Lingvay,Stewart Harris,Elmar Jaeckel,Keval Chandarana,Mattis F. Ranthe,Esteban Jódar

DOI: https://doi.org/10.1111/dom.13043

2017-07-31

Diabetes, Obesity and Metabolism

Abstract:This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2 ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.
A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.

Cesar Zambrano,G. Umpierrez,Bonnie S. Albury,P. Vellanki,M. F. Scioscia,Georgia M. Davis,Limin Peng,Jarrod Saling,F. Pasquel,Rodolfo J. Galindo,M. Fayfman,B. Moazzami

DOI: https://doi.org/10.2337/dc22-2426

2023-07-17

Diabetes Care

Abstract:OBJECTIVE In participants with type 2 diabetes (T2D) and HbA1c >9.0-10.0%, guidelines recommend treatment with basal-bolus insulin. RESEARCH DESIGN AND METHODS This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72). The primary end point was noninferiority (0.4%) in HbA1c reduction between groups. RESULTS Among 145 participants (HbA1c 10.8% ± 1.3), there was no statistically significant difference in HbA1c reduction (3.18% ± 2.29 vs. 3.00% ± 1.79, P = 0.65; estimated treatment difference (ETD) 0.18%, 95% CI -0.59, 0.94) between the IDegLira and basal-bolus groups. IDegLira resulted in significantly lower rates of hypoglycemia <70 mg/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less weight gain (1.24 ± 8.33 vs. 5.84 ± 6.18 kg, P = 0.001; ETD -4.60, 95% CI -7.33, -1.87). CONCLUSIONS In participants with T2D and HbA1c ≥9.0-15.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen.

Medicine
Intraoperative Dermatomal Evoked Potential Monitoring Fails to Predict Outcome From Lumbar Decompression Surgery

Richard Yen‐Chun Tsai,Rongxing Yang,M. Nuwer,L. Kanim,R. Delamarter,E. Dawson

DOI: https://doi.org/10.1097/00007632-199709010-00005

IF: 3.241

1997-09-01

Spine

Abstract:Study Design. Thirty‐three patients with single‐level, unilateral lumbosacral radiculopathy underwent microdecompression and intraoperative dermatomal evoked potential monitoring. Side‐to‐side latency asymmetry was calculated. A criteria for "abnormal" was defined. Intraoperative dermatomal evoked potentials were obtained before and after decompression. The changes were correlated with clinical outcome at the 3‐month follow‐up examination. Objectives. To determine whether intraoperative dermatomal evoked potential latency asymmetry confirms nerve root compression and whether an improvement of latency asymmetry after decompression predicts a good clinical outcome. Summary of Background Data. Intraoperative dermatomal evoked potential has been proposed as a test to assess the adequacy of nerve root decompression. Initial reports suggested improvement of dermatomal evoked potential amplitude and latency after decompression. The clinical efficacy is controversial because of its technical difficulty and inherent variation. Methods. Cervical recording was chosen to reduce the effects of anesthesia. The asymptomatic nerve root was used as a control. Quality of the tracings was determined by evoked potentials‐to‐noise amplitude ratio. Clinical outcome was based on patient's pain relief and satisfaction. Results. Tracings of acceptable quality were obtained at baseline in 57.6% (19 of 33) of patients. A side‐to‐side latency asymmetry > 5% was defined as abnormal. Before decompression, 68.4% (13 of 19) of patients had an abnormal dermatomal evoked potential. After decompression, latency asymmetry returned to normal in every patient. Clinical outcome was good or excellent in 13 patients, fair in four patients, and poor in two patients. Dermatomal evoked potential latency improvements were not related to variation in clinical outcome. Conclusions. Intraoperative dermatomal evoked potential monitoring is technically demanding. Finding reproducible potentials is difficult. More research is necessary before general use of dermatomal evoked potentials for monitoring nerve root decompression.
Concurrent Non-Malleable Witness Indistinguishable Argument from Any One-Way Function

Guifang Huang,Lei Hu

DOI: https://doi.org/10.1007/978-3-642-34704-7_25

2011-11-30

Abstract:
217-OR: A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira vs. Basal Bolus in Patients with Poorly Controlled Type 2 Diabetes and Very High HbA1c (>9%–15%) : IDegLira HIGH Trial

G. Umpierrez,P. Vellanki,M. F. Scioscia,Georgia M. Davis,Jarrod Saling,F. Pasquel,Rodolfo J. Galindo,A. Migdal,M. Fayfman,B. Moazzami

DOI: https://doi.org/10.2337/db22-217-or

IF: 7.7

2022-06-01

Diabetes

Abstract:IDegLira-HIGH trial was a non-inferiority, prospective, randomized clinical trial, comparing the efficacy and safety of insulin degludec/liraglutide combination (IDegLira) and a regimen of multiple daily injections (MDI) with basal-bolus insulin (BB) in adults (>18-80 years of age) , with type 2 diabetes (T2D) , and very high HbA1c (>9%-15%) , previously treated with basal insulin or multiple oral agents. Primary endpoint was change in HbA1c from baseline to week 26. Secondary endpoints included incidence of hypoglycemia, changes on weight and glycemic variability (% coefficient of variation [%CV]) . Treatment with IDegLira and BB insulin resulted in similar improvement in glycemic control: 7.7±1.7% and 7.7±1.5%, (p=0.76) , with a reduction from baseline of -3.2±2.3% and -3.0±1.8%, (p=0.39) at 26-weeks. IDegLira resulted in lower rates of hypoglycemia <70 mg/dl (22% vs. 36%, p=0.05) , similar glycemic variability (CGM %CV 30.4±9.1% vs. 33.2±7.3%, p=0.08) , and greater weight loss (-3.7±4.1 kg vs. +8.4±5.4 kg, p<0.01) compared to BB. IDegLira was associated with higher rates of nausea (Table 1) . Conclusions: In patients with T2D and very high HbA1c (≥9%-15%) , a regimen of daily IDegLira injection is non-inferior to MDI with BB insulin on HbA1c reduction and was associated with weight loss and less hypoglycemia. R.J.Galindo: Advisory Panel; Sanofi, WW International, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Novo Nordisk. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk. B.Moazzami: None. M.F.Scioscia: None. P.Vellanki: n/a. G.M.Davis: Consultant; Medscape, Research Support; Insulet Corporation. F.J.Pasquel: Consultant; AI Health LLC, Boehringer Ingelheim International GmbH, Dexcom, Inc., Research Support; Dexcom, Inc., Insulet Corporation, Merck & Co., Inc. M.Fayfman: None. A.L.Migdal: None. J.Saling: None. Investigator-initiated study to Emory University (PI. Dr. Rodolfo J. Galindo) from Novo Nordisk.

Medicine
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Ian Blumer,Jeremy H Pettus,Tricia Santos Cavaiola

DOI: https://doi.org/10.1080/00325481.2018.1450058

Abstract:Many individuals with type 2 diabetes (T2D) will eventually require insulin therapy to help achieve and maintain adequate glycemic control. However, the use of insulin can be associated with adverse effects such as hypoglycemia and weight gain, and in some patients the addition of insulin to treatment regimens is often still insufficient to achieve target glycemic control. Combining basal insulin with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with T2D has been demonstrated to be effective and well tolerated, while mitigating many of the adverse events associated with giving either of these drug classes alone. Two titratable, fixed-ratio combination therapies, iGlarLixi and IDegLira, that combine basal insulin and a GLP-1 RA in a once-daily subcutaneous injection are currently approved by the US Food and Drug Administration (FDA) for the treatment of patients with T2D. The fixed-ratio combination iGlarLixi combines insulin glargine 100 Units/mL with lixisenatide, while IDegLira combines insulin degludec 100 Units/mL with liraglutide. While these new fixed-ratio combinations contain antihyperglycemic medications that are familiar to most health care providers, there are many questions relating to their use when formulated as a fixed-ratio combination therapy. This article discusses the 'top 10' considerations that health care providers should know about these novel combination therapies as these agents begin to gain an increasing presence in clinical practice.
Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients

Caiyun Guo,Yang Lu

DOI: https://doi.org/10.2147/dmso.s472174

2024-09-01

Diabetes Metabolic Syndrome and Obesity Targets and Therapy

Abstract:Caiyun Guo, Yang Lu Department of Endocrinology, YuYao People's Hospital, Ningbo, Zhejiang Province, People's Republic of China Correspondence: Caiyun Guo, Department of Endocrinology, YuYao People's Hospital, 800 Chengdong Road, Ningbo, Zhejiang Province, 315400, People's Republic of China, Email Background: A short-term insulin intensive therapy is an important method used in clinical practice to control blood glucose, and a scientific post-treatment plan is key to long-term blood glucose stability control. This study aimed to investigate efficacy and safety of early conversion of intensive insulin therapy to IDegLira in T2DM patients. Methods: This study was a prospective study, involving 80 T2DM patients finally. Patients were firstly treated with insulin for intensified therapy (Pre-IDegLira group), then switched to insulin degludec and liraglutide (IDegLira) for 3 months (IDegLira-3 months group). Data including HbA1c, fasting blood glucose, fasting C-peptide, weight, insulin dosage, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were analyzed. Correlations between fasting blood glucose and other parameters were evaluated with Pearson correlation analysis. Results: IDegLira early conversion significantly reduced fasting blood glucose ( p < 0.001), weight ( p =0.015), and insulin dosage ( p =0.001) of T2DM patients compared to those of Pre-IDegLira group. HbA1c level was remarkably lower in T2DM patients underwent IDegLira early conversion compared to that in Pre-IDegLira group ( p < 0.001), with HbA1c < 7% proportion of 73.75% (59/80). IDegLira early conversion significantly downregulated levels of TC ( p < 0.001), TG ( p < 0.001), LDL-C ( p < 0.001), and upregulated HDL-C level ( p =0.017) of T2DM patients, compared to those in Pre-IDegLira group. IDegLira early conversion markedly reduced ALT ( p < 0.001) and AST ( p =0.002) levels of T2DM patients compared to those in Pre-IDegLira group. IDegLira early conversion demonstrated a positive correlation between fasting blood glucose and HbA1c ( r =0.531, p < 0.001) or TG level ( r =0.336, p =0.002) in T2DM patients. Conclusion: Early conversion of intensive insulin therapy to IDegLira effectively reduced fasting blood glucose and HbA1c in T2DM patients with higher safety. Keywords: insulin intensive therapy, IDegLira, T2DM, early conversion, safety In recent 30 years, the prevalence of diabetes mellitus in China has increased significantly. 1,2 The epidemiological survey of diabetes mellitus conducted by the Endocrinology Branch of the Chinese Medical Association in 31 provinces from 2015 to 2017 showed that the prevalence rate of diabetes mellitus among people aged 18 years and above in China was 11.2%, the treatment rate was 32.2%, and the control rate was 49.2%. 3 The metabolic control of type 2 diabetes (T2DM) is still a huge challenge. The ideal treatment plan for diabetes mellitus should reduce the risk of weight gain and hypoglycemia as much as possible on the basis of effectively reducing the blood sugar level, with less adverse reactions and good compliance. Basic insulin supplements exogenous basic insulin, inhibits liver glycolysis and gluconeogenesis, reduces liver glucose output, increases skeletal muscle glucose uptake, and effectively controls fasting blood sugar. 4 The use of glucagon like peptide-1 receptor agonist (GLP-1RA) alone, 5 combined with basal insulin, can reduce the risk of hypoglycemia and weight loss. 6–8 However, both are injectable preparations, and the increased complexity of the treatment plan may reduce patient compliance. In 2020, ADA medical diagnosis and treatment standards for diabetes recommend a compound preparation of basic insulin combined with GLP-1RA at a fixed proportion. 9 Insulin degludec and liraglutide (IDegLira) is the world's first marketed combination of basal insulin and GLP-1RA, which can exert complementary regulatory metabolic effects on multiple target organs of T2DM. It is a new choice after insulin intensive therapy. A previous study 10 has shown that after 26 weeks of treatment with IDegLira, patients have significantly improved (decreased) HbA1c and a lower risk of hypoglycemia. Therefore, IDegLira can become a new option for initiating and optimizing insulin therapy in Chinese T2DM patients. This study investigated the efficacy and safety of early conversion of intensive insulin therapy to IDegLira in T2DM patients. After controlling blood glucose levels in pat -Abstract Truncated-

endocrinology & metabolism
Hepatocellular carcinoma in immigrants to the United Kingdom.

S. Zaman,P. Johnson,R. Williams

DOI: https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A068038

1986-08-01

Abstract:Analysis of the origin of patients with hepatocellular carcinoma admitted to the Liver Unit between 1970 and July 1985 showed an increase in frequency of this tumour in immigrants to the United Kingdom from none between 1970 and 1973, to 15 per cent between 1981 and 1985. The 19 immigrant cases had resided in this country for between four and 28 years and when compared with a group of 30 patients born in the United Kingdom three striking differences emerged. Firstly, the immigrants were significantly younger. Secondly, although the frequency of underlying cirrhosis (approximately 80 per cent) was similar the aetiology differed with HBV-related disease being the largest group (93 per cent) in the immigrants and alcohol or cryptogenic cirrhosis in the other patients amongst whom HBV markers were detected in only 20 per cent. Thirdly, whilst signs and symptoms attributable to hepatocellular carcinoma represented the first evidence of liver disease in 89 per cent of the immigrants, symptoms of cirrhosis in patients born in the United Kingdom had been evident for several years before tumour development.
Assessment of viability of human fat injection into nude mice with micro-computed tomography.

David A. Atashroo,Kevin J. Paik,M. Chung,A. McArdle,K. Senarath-Yapa,Elizabeth R. Zielins,R. Tevlin,Christopher R Duldulao,G. Walmsley,Taylor L. Wearda,O. Marecic,M. Longaker,D. Wan

DOI: https://doi.org/10.3791/52217

2015-01-07

Journal of Visualized Experiments

Abstract:Lipotransfer is a vital tool in the surgeon's armamentarium for the treatment of soft tissue deficits of throughout the body. Fat is the ideal soft tissue filler as it is readily available, easily obtained, inexpensive, and inherently biocompatible.(1) However, despite its burgeoning popularity, fat grafting is hampered by unpredictable results and variable graft survival, with published retention rates ranging anywhere from 10-80%. (1-3) To facilitate investigations on fat grafting, we have therefore developed an animal model that allows for real-time analysis of injected fat volume retention. Briefly, a small cut is made in the scalp of a CD-1 nude mouse and 200-400 µl of processed lipoaspirate is placed over the skull. The scalp is chosen as the recipient site because of its absence of native subcutaneous fat, and because of the excellent background contrast provided by the calvarium, which aids in the analysis process. Micro-computed tomography (micro-CT) is used to scan the graft at baseline and every two weeks thereafter. The CT images are reconstructed, and an imaging software is used to quantify graft volumes. Traditionally, techniques to assess fat graft volume have necessitated euthanizing the study animal to provide just a single assessment of graft weight and volume by physical measurement ex vivo. Biochemical and histological comparisons have likewise required the study animal to be euthanized. This described imaging technique offers the advantage of visualizing and objectively quantifying volume at multiple time points after initial grafting without having to sacrifice the study animal. The technique is limited by the size of the graft able to be injected as larger grafts risk skin and fat necrosis. This method has utility for all studies evaluating fat graft viability and volume retention. It is particularly well-suited to providing a visual representation of fat grafts and following changes in volume over time.
Australian Parent and Teacher Ratings of the DSM-IV ADHD Symptoms

R. Gomez

DOI: https://doi.org/10.1177/1087054706295665

2007-07-01

Journal of Attention Disorders

Abstract:Objective: The aims of the study were to examine differential symptom functioning (DSF) and agreement across parent and teacher ratings for the DSM-IV ADHD inattention (IA) and hyperactivity/impulsivity (HI) symptoms, listed in the Disruptive Behavior Rating Scale (DBRS). Method: DSF was examined using a parametric technique involving ordinal logistic regression, and also a nonparametric technique known as kernel smoothing implemented in the program TestGraf. To accomplish the aims, Australian parents and teachers completed the DBRS for 213 children, between 6 and 11 years of age. Results: The results of both analytical procedures showed no DSF across all the IA and HI symptoms. Additional results indicated low parent-teacher agreement. Conclusion: The absence of DSF suggests that previous reports of low parent-teacher agreement are likely to reflect a true state of affairs and that parent and teacher ratings can be compared. In this context, the low parent-teacher agreement can be interpreted as indication that the attention deficit hyperactivity disorder (ADHD) symptoms are situation specific. (J. of Att. Dis. 2007; 11(1) 17-27)
IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

Maria Elena Malighetti,Laura Molteni,Emanuela Orsi,Roberta Serra,Alessia Gaglio,Federica Mazzoleni,Filomena Russo,Antonio Carlo Bossi

DOI: https://doi.org/10.1007/s00592-024-02361-7

2024-09-05

Abstract:Aims: To assess the effects of IDegLira on glucometric indices deriving from intermittently scanned Continuous Glucose Monitoring (isCGM) in patients with type 2 diabetes (T2D). Methods: Retrospective, observational, cohort, multi-center, "pre - post" study. All adults consecutively identified in the medical records who started treatment with IDegLira, and for whom an isCGM report before and after the initiation of IDegLira was available were included in the study. Time in range (TIR) represented the primary endpoint. Additional glucometric indices, insulin doses and body weight were also assessed. Results: Overall, 87 patients were included by 5 diabetes centers [mean age 70.2 ± 11.0 years, mean duration of T2D 15.5 ± 9.6 years; BMI 29.4 ± 5.4 kg/m2, baseline HbA1c 9.1 ± 2.1%, 33% insulin naïve, 20.7% treated with basal-oral therapy (BOT), and 46% treated with multiple daily injections of insulin (MDI)]. After an average of 1.7 weeks from IDegLira initiation, TIR significantly increased from 56.8 ± 23.5% to 81.3 ± 13.5% (p < 0.0001), TAR decreased from 42.3 ± 24.2% to 17.1 ± 13.6% (p < 0.0001), while TBR remained steadily low (from 1.3 ± 2.3% to 1.4 ± 2.6%; p = 0.62). Estimated HbA1c decreased from 9.1 ± 2.1% to 6.7 ± 0.6% (p < 0.0001) and percentage of patients with a blood glucose coefficient of variation ≥ 36% dropped from 33.2 to 13.8% (p = 0.0005). In patients on MDI, the reduction in the total insulin dose was substantial (from 55.8 ± 31.2 IU to 27.2 ± 12.3 U). Conclusions: In T2D patients with poor metabolic control, either insulin naïve or treated with BOT or MDI, the introduction of IDegLira produces a significant increase in the time spent in good metabolic control and a marked reduction in glycemic fluctuations.
Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months

Emil Martinka,Ingrid Dravecká,Ivan Tkáč

DOI: https://doi.org/10.1007/s13300-023-01435-z

2023-07-06

Diabetes Therapy

Abstract:This study aimed to evaluate the effectiveness and safety of switching from basal bolus insulin treatment (BBIT) to a fixed combination of insulin degludec and liraglutide (IDegLira) in patients with type 2 diabetes mellitus (T2DM) who had preserved insulin secretion but inadequate glucose control. The study also aimed to assess the feasibility of implementing this therapeutic approach in common clinical practice settings.

endocrinology & metabolism
Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

Lyudmila Alexandrovna Ruyatkina,Maxim Sorokin

DOI: https://doi.org/10.14341/7875

2017-06-20

Diabetes Mellitus

Abstract:Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analogue) with liraglutide (GLP-1 analogue) reduces fasting and postprandial glycaemia, lowers the risk of hypoglycaemia and does not have a negative impact on body weight. In this literature review, the pharmacodynamic and pharmacokinetic profiles, as well as the potential benefits of combined insulin detemir and liraglutide therapy on diabetic nephropathy and high cardiovascular disease risk were determined. Data from randomised clinical trials and the National Registry were used to assess the clinical efficacy of combined insulin detemir and liraglutide therapy. The different mechanistic actions of insulin detemir and liraglutide resulted in an additive glucose-lowering effect, which did not affect the pharmacodynamic and pharmacokinetic profiles of each therapeutic agent.

[Determination of the quantum requirements for photosynthesis by very thin cell suspensions].

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

Continuous brainstem auditory evoked potential monitoring during nocturnal sleep.

Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges

Collaborative Filtering for Predicting Users' Potential Preferences

Prognosis of cerebral embolism.

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.

Intraoperative Dermatomal Evoked Potential Monitoring Fails to Predict Outcome From Lumbar Decompression Surgery

Concurrent Non-Malleable Witness Indistinguishable Argument from Any One-Way Function

217-OR: A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira vs. Basal Bolus in Patients with Poorly Controlled Type 2 Diabetes and Very High HbA1c (>9%–15%) : IDegLira HIGH Trial

Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients

Hepatocellular carcinoma in immigrants to the United Kingdom.

Assessment of viability of human fat injection into nude mice with micro-computed tomography.

Australian Parent and Teacher Ratings of the DSM-IV ADHD Symptoms

IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance